Questions from the public: November 2021 Board meeting

# How will the NICE Board be responding to the feedback from stakeholders on the methods and process review consultation? We have had significant concerns about the changes being made in a cost neutral way - which means to make progress for some patients it is at the cost for others.

The extensive feedback from the consultation is currently being reviewed and will be considered by the working groups. A report on the consultation feedback will be brought to the January Board meeting along with the final methods and process manual for approval.

# Are there plans to consult with stakeholders on the inequalities calculator? This is a very positive development.

NICE is trialling the calculator on behalf of the University of York and any decisions on wider engagement will be a matter for the University to consider.

# What are the latest developments on the Innovative Medicines Fund? How will that interact with NICE’s new methods and processes?

A standard operating procedure for the Innovative Medicines Fund (IMF) is being developed for joint consultation by NICE and NHS England and Improvement. The new methods and processes will inform which technologies enter into the IMF.

# Will any ‘quick wins’ be implemented before the January board meeting?

An implementation plan will be developed, but changes will not be implemented before the January Board meeting.

# What steps can be taken to ensure the timely supply of medications manufactured and obtained from EU countries?

NICE isn't directly involved in supply and manufacturing although we do support our partners and government as part of our wider partnership in the life sciences sector.

# NICE without question is internationally recognised as best in class. However NICE is an organisation, not a ''process''. Do you think NICE is doing sufficient to educate on the various programmes it undertakes, or conversely do NICE play in too many spaces. A thinning/amalgamation of programmes may enhance both national and international reputation?

Thank you for your comments and feedback. The intention of the strategy is to prioritise and focus our work into two core areas: technology evaluation; and dynamic living guidelines. These will both be underpinned by ongoing development of methods and process, including an increasing use of real world data.

# Do differences in healthcare systems in different countries limit the translatability of guidance on cost-effectiveness from one country to another? If so, what can be done to overcome this?

NICE recommendations cannot simply be implemented in other countries and need contextualising to take account of the health and care system in place. There is a methodology in place for undertaking this contextualisation for guidelines.

# Will NICE be working with the successor to Public Health England to improve the uptake of guidelines?

Yes, NICE is working with the successor organisations to Public Health England to confirm the best approach for future collaboration.